AstraZeneca has reported a strong third-quarter performance, with core earnings per share rising by 14% year-on-year and revenue increasing to $15.19 billion. This growth is attributed to the strength of its pipeline and a favorable pricing deal in the U.S. This is significant as it highlights the company's ability to innovate and maintain financial health in a competitive market, which could lead to further investments in research and development.